Clinical trials: CIPN - Chemotherapy-Induced Peripheral Neuropathy
- Condition CIPN - Chemotherapy-Induced Peripheral Neuropathy
- Funder type Industry (pharma, biotech, devices)
- Accepts healthy volunteers yes
Chemotherapy Induced Peripheral Neuropathy (CIPN)
SUNCIST: A Study of Calmangafodipir in Healthy Japanese and Caucasian Subjects
Randomized, double-bline, placebo-controlled, single dose study comparing the pharmacokinetics (PK) and safety of PP095-01 in Japanese and non-Asian (eg, Caucasian) subjects.
- Trial name
- NCT03430999
- Testing
- Calmangafodipir
- Where
- United States
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Egetis Therapeutics AB (publ)
Chemotherapy-induced Peripheral Neuropathy (CIPN)
Safety, Tolerability, and PK of AH-008 Following Single Ascending Dose in Healthy Subjects
This is a Phase 1, first-in-human (FIH), randomized, double-blind, placebo-controlled, parallel-group, single ascending dose (SAD) study to evaluate the safety, tolerability, and pharmacokinetics of AH-008 administered as a…
- Trial name
- NCT07697560
- Testing
- AH-008 for Injection, 150 mg
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- AnHorn Medicines Co. Ltd.
Peripheral Nervous System Diseases
Pre-study to Evaluate IENFD Induction in Patients With Taxane-induced CIPN
This is a non-interventional study examining IENFD levels in patients with CIPN after taxane chemotherapy and in age-matched healthy subjects.
- Trial name
- NCT05133947
- Testing
- Non interventional
- Where
- China
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Beijing 3E-Regenacy Pharmaceuticals Co., Ltd.